Health Tech Capitol | Cellectar Provides Myeloma Study Update
15980
post-template-default,single,single-post,postid-15980,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Cellectar Provides Myeloma Study Update

08 Aug Cellectar Provides Myeloma Study Update

Posted at 12:55h in Uncategorized by
0 Likes

Cellectar Biosciences’ CLR 131 has achieved an overall survival of greater than 22 months in advanced multiple myeloma patients, the company announced today.

“We continue to make meaningful progress on our CLR 131 program and are encouraged by the observed clinical outcomes to date,” Cellectar Biosciences President and CEO Jim Caruso said in a statement. “We look forward to reporting data from the fourth cohort of our Phase 1 trial as well as the single and multi-dose Phase 2 study when available.”

Read more at Madison Startups

No Comments

Sorry, the comment form is closed at this time.